<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00716443</url>
  </required_header>
  <id_info>
    <org_study_id>US10098</org_study_id>
    <nct_id>NCT00716443</nct_id>
  </id_info>
  <brief_title>Evaluate Efficacy, Safety &amp; Subject Satisfaction of Pain Management With Pliaglis® Cream for Dermal Filler Injections</brief_title>
  <official_title>Open-Label, Randomized, Split-Face Study to Evaluate the Efficacy, Safety and Subject Satisfaction of Pain Management During and After Restylane® Dermal Filler Injections for the Correction of Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma Laboratories, L.P.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma Laboratories, L.P.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pliaglis® Cream versus compounded topical anesthetic for pain management during Restylane®
      injections for the correction of nasolabial folds.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label, randomized study designed to assess the effectiveness of a topical anesthetic
      (Pliaglis® Cream) versus a compounded topical anesthetic at needle stick, immediately after,
      one and three hours after Restylane® injections in the nasolabial folds.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject's Pain Evaluation by Visual Analog Scale (VAS)Upon First Needlestick, Immediately After Injection, One Hour After Injection and Three Hours After Injection of Restylane® Into the Nasolabial Folds</measure>
    <time_frame>upon first needlestick, immediately after injection, one hour after injection and three hours after injection of Restylane® into the nasolabial folds</time_frame>
    <description>Subject's pain as evaluated using a VAS scale from 0 - 10 cm (centimeters) with 0 cm being no pain and 10 cm being the worst pain imaginable upon first needlestick, immediately after injection, one hour after injection and three hours after injection of Restylane® into the nasolabial folds</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Answered the Question &quot;What Level of Pain Did You Experience When You Were Injected?&quot; Three Hours After Injection of Restylane® Into the Nasolabial Folds</measure>
    <time_frame>three hours after injection of Restylane® into the nasolabial folds</time_frame>
    <description>Number of participants who answered according to a scale of None, Minimal, Mild, Moderate, Severe, or No response to the question &quot;What level of pain did you experience when you were injected?&quot; three hours after injection of Restylane® into the nasolabial folds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Answered the Question &quot;If You Experienced Pain, Was it What You Expected From the Injection Procedure?&quot; Three Hours After Injection of Restylane® Into the Nasolabial Folds</measure>
    <time_frame>three hours after injection of Restylane® into the nasolabial folds</time_frame>
    <description>Number of participants who answered No, Yes, Had no expectations or No response to the question &quot;If you experienced pain, was it what you expected from the injection procedure?&quot; three hours after injection of Restylane® into the nasolabial folds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Answered the Question &quot;If it Was Different Than What You Expected, Was it?&quot; Three Hours After Injection of Restylane® Into the Nasolabial Folds</measure>
    <time_frame>three hours after injection of Restylane® into the nasolabial folds</time_frame>
    <description>Number of participants who answered the question &quot;If it was different than what you expected, was it?&quot; (More pain, Less pain or No response) three hours after injection of Restylane® into the nasolabial folds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Answered the Question &quot;Still Speaking to the Topical Anesthetic You Had on the Right/Left Side of Your Face, Would You Recommend it to Your Friend or Family Member?&quot; 3 Hours After Injection of Restylane® Into Nasolabial Folds</measure>
    <time_frame>three hours after injection of Restylane® into the nasolabial folds</time_frame>
    <description>Number of participants who answered No, Yes or No response to the question &quot;Still speaking to the topical anesthetic you had on the right/left side of your face, would you recommend it to your friend or family member?&quot; three hours after injection of Restylane® into the nasolabial folds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Each Category of the Investigator Evaluation of the Subject's Post Procedure Pain Assessment Scale Upon First Needle Stick of Injection of Restylane® Into the Nasolabial Folds</measure>
    <time_frame>Upon first needle stick of injection of Restylane® into the nasolabial folds</time_frame>
    <description>Number of participants in each category of the Investigator Evaluation of the Subject's Post Procedure Pain Assessment scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) upon first needle stick of an injection of Restylane® into the nasolabial folds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Each Category of the Investigator Evaluation of the Subject's Post Procedure Pain Assessment Scale Immediately After Injection of Restylane® Into the Nasolabial Folds</measure>
    <time_frame>immediately after injection of Restylane® into the nasolabial folds</time_frame>
    <description>Number of participants in each category of the Investigator Evaluation of the Subject's Post Procedure Pain Assessment scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) immediately after injection of Restylane® into the nasolabial folds immediately after injection of Restylane® into the nasolabial folds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Each Category of the Investigator's Evaluation of Subject's Pain Scale One Hour After Injection of Restylane® Into the Nasolabial Folds</measure>
    <time_frame>one hour after injection of Restylane® into the nasolabial folds</time_frame>
    <description>Number of participants in each category of the Investigator's Evaluation of Subject's Pain scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) one hour after injection of Restylane® into the nasolabial folds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Each Category of the Investigator's Evaluation of Subject's Pain Scale Three Hours After Injection of Restylane® Into the Nasolabial Folds</measure>
    <time_frame>three hours after injection of Restylane® into the nasolabial folds</time_frame>
    <description>Number of participants in each category of the Investigator's Evaluation of Subject's Pain scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) three hours after injection of Restylane® into the nasolabial folds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Each Category of the Blinded Evaluator's Evaluation of Subject's Pain Scale Upon First Needle Stick of Injection of Restylane® Into the Nasolabial Folds</measure>
    <time_frame>upon first needle stick of injection of Restylane® into the nasolabial folds</time_frame>
    <description>Number of participants in each category of the Blinded Evaluator's Evaluation of Subject's Pain scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) upon first needle stick of an injection of Restylane® into the nasolabial folds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Each Category of the Blinded Evaluator's Evaluation of Subject's Pain Scale Immediately After Injection of Restylane® Into the Nasolabial Folds</measure>
    <time_frame>immediately after injection of Restylane® into the nasolabial folds</time_frame>
    <description>Number of participants in each category of the Blinded Evaluator's Evaluation of Subject's Pain scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) immediately after injection of Restylane® into the nasolabial folds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Each Category of the Blinded Evaluator's Evaluation of Subject's Pain Scale One Hour After Injection of Restylane® Into the Nasolabial Folds</measure>
    <time_frame>one hour after injection of Restylane® into the nasolabial folds</time_frame>
    <description>Number of participants in each category of the Blinded Evaluator's Evaluation of Subject's Pain scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) one hour after an injection of Restylane® into the nasolabial folds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Each Category of the Blinded Evaluator's Evaluation of Subject's Pain Scale Three Hours After Injection of Restylane® Into the Nasolabial Folds</measure>
    <time_frame>three hours after injection of Restylane® into the nasolabial folds</time_frame>
    <description>Number of participants in each category of the Blinded Evaluator's Evaluation of Subject's Pain scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) three hours after injection of Restylane® into the nasolabial folds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Yes/no Answers to Question to Investigator &quot;Did the Topical Anesthetics Provide Adequate Anesthesia for the Injections of Restylane® Into the Nasolabial Folds Procedure?&quot; Day of Injection of Restylane® Into Nasolabial Folds</measure>
    <time_frame>Day of injection of Restylane® into the nasolabial folds</time_frame>
    <description>Number of participants with yes or no answers to question asked to investigator on the day of injection of Restylane® into the nasolabial folds &quot;Did the topical anesthetics provided adequate anesthesia for the injections of Restylane® into the nasolabial folds procedure?&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Tolerability Assessments Resulting in Adverse Events From Baseline to Two Days After Injection of Restylane® Into the Nasolabial Folds</measure>
    <time_frame>Baseline to two days after injection of Restylane® into the nasolabial folds</time_frame>
    <description>Number of participants w/ tolerability assessments (erythema, edema, blanching) resulting in adverse events from Baseline to two days after injection of Restylane® into the nasolabial folds</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Nasolabial Folds</condition>
  <arm_group>
    <arm_group_label>Pliaglis® Cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tetracaine 4% / lidocaine 7% cream; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>benzocaine 20% / lidocaine 6% / tetracaine 4% ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tetracaine 7% / lidocaine 7% cream (Pliaglis® Cream)</intervention_name>
    <description>Apply tetracaine/lidocaine cream once on one side of the face prior to Restylane® injections</description>
    <arm_group_label>Pliaglis® Cream</arm_group_label>
    <other_name>Pliaglis® Cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>benzocaine 20% / lidocaine 6% / tetracaine 4% ointment</intervention_name>
    <description>apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections</description>
    <arm_group_label>Pliaglis® Cream</arm_group_label>
    <arm_group_label>benzocaine 20% / lidocaine 6% / tetracaine 4% ointment</arm_group_label>
    <other_name>BLT ointment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female Subjects 30 - 65 years of age

          -  Subject undergoing cosmetic dermal filler injections for correction of nasolabial
             folds. Treatment sites should be comparable, requiring the same number of injections
             on each nasolabial fold

          -  Subjects diagnosed with moderate nasolabial folds (Wrinkle Severity Rating Scale of
             grade 3)

        Exclusion Criteria:

          -  Subjects under treatment for a dermatologic condition on the face, which may interfere
             with the safe evaluation of the study treatment (e.g. eczema, psoriasis, severe
             sun-damage, dermatitis), have damaged, denuded or broken skin at the designated
             treatment site and/or have scarring or infection of the area to be treated

          -  Subjects who have taken prescription or non-prescription analgesic medication during
             the 24 hour period prior to the procedure

          -  Subjects with a history of bleeding or clotting disorders

          -  Subjects who have used ASA (aspirin), NSAIDs (Non-Steroidal Anti- inflammatory Drugs),
             anticoagulants, St. John's Wort or high doses of Vitamin E (above the recommended
             daily allowance) within 2 weeks prior to the procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald W Gottschalk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma Laboratories, L.P.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin and Cancer Associates, Center for Cosmetic Enhancement</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Esthetic Dermatology and Laser Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sadick Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2008</study_first_submitted>
  <study_first_submitted_qc>July 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2008</study_first_posted>
  <results_first_submitted>September 25, 2009</results_first_submitted>
  <results_first_submitted_qc>January 8, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 1, 2010</results_first_posted>
  <last_update_submitted>September 21, 2012</last_update_submitted>
  <last_update_submitted_qc>September 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nasolabial folds</keyword>
  <keyword>wrinkles</keyword>
  <keyword>topical anesthetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Tetracaine</mesh_term>
    <mesh_term>Benzocaine</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dates of recruitment period: First subject was enrolled on July 30, 2008 and the last subject was enrolled on September 8, 2008.</recruitment_details>
      <pre_assignment_details>The wash-out period prior to baseline was 24 hrs for analgesic medication; 14 days for aspirin (ASA), non-steroidal anti-inflammatory drugs (NSAIDs), anticoagulants, St. John's Wort or doses of Vitamin E above the recommended daily allowance; 14 days for sunburn/tanning bed exposure; 12 months for filler injections into the nasolabial folds.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pliaglis® Cream and Compounded Topical Anesthetic Ointment</title>
          <description>Apply Pliaglis® Cream on one side of the face and compounded topical anesthetic ointment on the other side of the face; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and compounded topical anesthetic ointment was used on the other side of the face prior to injection of Restylane® into the nasolabial folds.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pliaglis® Cream and Compounded Topical Anesthetic Ointment</title>
          <description>Apply Pliaglis® Cream on one side of the face and compounded topical anesthetic ointment on the other side of the face; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and compounded topical anesthetic ointment was used on the other side of the face prior to injection of Restylane® into the nasolabial folds.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" spread="8.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subject's Pain Evaluation by Visual Analog Scale (VAS)Upon First Needlestick, Immediately After Injection, One Hour After Injection and Three Hours After Injection of Restylane® Into the Nasolabial Folds</title>
        <description>Subject's pain as evaluated using a VAS scale from 0 - 10 cm (centimeters) with 0 cm being no pain and 10 cm being the worst pain imaginable upon first needlestick, immediately after injection, one hour after injection and three hours after injection of Restylane® into the nasolabial folds</description>
        <time_frame>upon first needlestick, immediately after injection, one hour after injection and three hours after injection of Restylane® into the nasolabial folds</time_frame>
        <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Pliaglis® Cream</title>
            <description>Pliaglis® Cream</description>
          </group>
          <group group_id="O2">
            <title>Compounded Topical Anesthetic Ointment</title>
            <description>compounded topical anesthetic ointment</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Pain Evaluation by Visual Analog Scale (VAS)Upon First Needlestick, Immediately After Injection, One Hour After Injection and Three Hours After Injection of Restylane® Into the Nasolabial Folds</title>
          <description>Subject's pain as evaluated using a VAS scale from 0 - 10 cm (centimeters) with 0 cm being no pain and 10 cm being the worst pain imaginable upon first needlestick, immediately after injection, one hour after injection and three hours after injection of Restylane® into the nasolabial folds</description>
          <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>upon first needle stick</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.07"/>
                    <measurement group_id="O2" value="2.8" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>immediately after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="2.14"/>
                    <measurement group_id="O2" value="2.8" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>one hour after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.12"/>
                    <measurement group_id="O2" value="0.6" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>three hours after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.14"/>
                    <measurement group_id="O2" value="0.5" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Answered the Question &quot;What Level of Pain Did You Experience When You Were Injected?&quot; Three Hours After Injection of Restylane® Into the Nasolabial Folds</title>
        <description>Number of participants who answered according to a scale of None, Minimal, Mild, Moderate, Severe, or No response to the question &quot;What level of pain did you experience when you were injected?&quot; three hours after injection of Restylane® into the nasolabial folds</description>
        <time_frame>three hours after injection of Restylane® into the nasolabial folds</time_frame>
        <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Pliaglis® Cream</title>
            <description>Pliaglis® Cream</description>
          </group>
          <group group_id="O2">
            <title>Compounded Topical Anesthetic Ointment</title>
            <description>compounded topical anesthetic ointment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Answered the Question &quot;What Level of Pain Did You Experience When You Were Injected?&quot; Three Hours After Injection of Restylane® Into the Nasolabial Folds</title>
          <description>Number of participants who answered according to a scale of None, Minimal, Mild, Moderate, Severe, or No response to the question &quot;What level of pain did you experience when you were injected?&quot; three hours after injection of Restylane® into the nasolabial folds</description>
          <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Answered the Question &quot;If You Experienced Pain, Was it What You Expected From the Injection Procedure?&quot; Three Hours After Injection of Restylane® Into the Nasolabial Folds</title>
        <description>Number of participants who answered No, Yes, Had no expectations or No response to the question &quot;If you experienced pain, was it what you expected from the injection procedure?&quot; three hours after injection of Restylane® into the nasolabial folds</description>
        <time_frame>three hours after injection of Restylane® into the nasolabial folds</time_frame>
        <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Pliaglis® Cream</title>
            <description>Pliaglis® Cream</description>
          </group>
          <group group_id="O2">
            <title>Compounded Topical Anesthetic Ointment</title>
            <description>compounded topical anesthetic ointment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Answered the Question &quot;If You Experienced Pain, Was it What You Expected From the Injection Procedure?&quot; Three Hours After Injection of Restylane® Into the Nasolabial Folds</title>
          <description>Number of participants who answered No, Yes, Had no expectations or No response to the question &quot;If you experienced pain, was it what you expected from the injection procedure?&quot; three hours after injection of Restylane® into the nasolabial folds</description>
          <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Had no expectations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Answered the Question &quot;If it Was Different Than What You Expected, Was it?&quot; Three Hours After Injection of Restylane® Into the Nasolabial Folds</title>
        <description>Number of participants who answered the question &quot;If it was different than what you expected, was it?&quot; (More pain, Less pain or No response) three hours after injection of Restylane® into the nasolabial folds</description>
        <time_frame>three hours after injection of Restylane® into the nasolabial folds</time_frame>
        <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Pliaglis® Cream</title>
            <description>Pliaglis® Cream</description>
          </group>
          <group group_id="O2">
            <title>Compounded Topical Anesthetic Ointment</title>
            <description>compounded topical anesthetic ointment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Answered the Question &quot;If it Was Different Than What You Expected, Was it?&quot; Three Hours After Injection of Restylane® Into the Nasolabial Folds</title>
          <description>Number of participants who answered the question &quot;If it was different than what you expected, was it?&quot; (More pain, Less pain or No response) three hours after injection of Restylane® into the nasolabial folds</description>
          <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>More pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Less pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Answered the Question &quot;Still Speaking to the Topical Anesthetic You Had on the Right/Left Side of Your Face, Would You Recommend it to Your Friend or Family Member?&quot; 3 Hours After Injection of Restylane® Into Nasolabial Folds</title>
        <description>Number of participants who answered No, Yes or No response to the question &quot;Still speaking to the topical anesthetic you had on the right/left side of your face, would you recommend it to your friend or family member?&quot; three hours after injection of Restylane® into the nasolabial folds</description>
        <time_frame>three hours after injection of Restylane® into the nasolabial folds</time_frame>
        <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Pliaglis® Cream</title>
            <description>Pliaglis® Cream</description>
          </group>
          <group group_id="O2">
            <title>Compounded Topical Anesthetic Ointment</title>
            <description>compounded topical anesthetic ointment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Answered the Question &quot;Still Speaking to the Topical Anesthetic You Had on the Right/Left Side of Your Face, Would You Recommend it to Your Friend or Family Member?&quot; 3 Hours After Injection of Restylane® Into Nasolabial Folds</title>
          <description>Number of participants who answered No, Yes or No response to the question &quot;Still speaking to the topical anesthetic you had on the right/left side of your face, would you recommend it to your friend or family member?&quot; three hours after injection of Restylane® into the nasolabial folds</description>
          <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Each Category of the Investigator Evaluation of the Subject's Post Procedure Pain Assessment Scale Upon First Needle Stick of Injection of Restylane® Into the Nasolabial Folds</title>
        <description>Number of participants in each category of the Investigator Evaluation of the Subject's Post Procedure Pain Assessment scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) upon first needle stick of an injection of Restylane® into the nasolabial folds</description>
        <time_frame>Upon first needle stick of injection of Restylane® into the nasolabial folds</time_frame>
        <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Pliaglis® Cream</title>
            <description>Pliaglis® Cream</description>
          </group>
          <group group_id="O2">
            <title>Compounded Topical Anesthetic Ointment</title>
            <description>compounded topical anesthetic ointment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Each Category of the Investigator Evaluation of the Subject's Post Procedure Pain Assessment Scale Upon First Needle Stick of Injection of Restylane® Into the Nasolabial Folds</title>
          <description>Number of participants in each category of the Investigator Evaluation of the Subject's Post Procedure Pain Assessment scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) upon first needle stick of an injection of Restylane® into the nasolabial folds</description>
          <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Each Category of the Investigator Evaluation of the Subject's Post Procedure Pain Assessment Scale Immediately After Injection of Restylane® Into the Nasolabial Folds</title>
        <description>Number of participants in each category of the Investigator Evaluation of the Subject's Post Procedure Pain Assessment scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) immediately after injection of Restylane® into the nasolabial folds immediately after injection of Restylane® into the nasolabial folds</description>
        <time_frame>immediately after injection of Restylane® into the nasolabial folds</time_frame>
        <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Pliaglis® Cream</title>
            <description>Pliaglis® Cream</description>
          </group>
          <group group_id="O2">
            <title>Compounded Topical Anesthetic Ointment</title>
            <description>compounded topical anesthetic ointment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Each Category of the Investigator Evaluation of the Subject's Post Procedure Pain Assessment Scale Immediately After Injection of Restylane® Into the Nasolabial Folds</title>
          <description>Number of participants in each category of the Investigator Evaluation of the Subject's Post Procedure Pain Assessment scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) immediately after injection of Restylane® into the nasolabial folds immediately after injection of Restylane® into the nasolabial folds</description>
          <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Each Category of the Investigator's Evaluation of Subject's Pain Scale One Hour After Injection of Restylane® Into the Nasolabial Folds</title>
        <description>Number of participants in each category of the Investigator's Evaluation of Subject's Pain scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) one hour after injection of Restylane® into the nasolabial folds</description>
        <time_frame>one hour after injection of Restylane® into the nasolabial folds</time_frame>
        <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Pliaglis® Cream</title>
            <description>Pliaglis® Cream</description>
          </group>
          <group group_id="O2">
            <title>Compounded Topical Anesthetic Ointment</title>
            <description>compounded topical anesthetic ointment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Each Category of the Investigator's Evaluation of Subject's Pain Scale One Hour After Injection of Restylane® Into the Nasolabial Folds</title>
          <description>Number of participants in each category of the Investigator's Evaluation of Subject's Pain scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) one hour after injection of Restylane® into the nasolabial folds</description>
          <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Each Category of the Investigator's Evaluation of Subject's Pain Scale Three Hours After Injection of Restylane® Into the Nasolabial Folds</title>
        <description>Number of participants in each category of the Investigator's Evaluation of Subject's Pain scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) three hours after injection of Restylane® into the nasolabial folds</description>
        <time_frame>three hours after injection of Restylane® into the nasolabial folds</time_frame>
        <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Pliaglis® Cream</title>
            <description>Pliaglis® Cream</description>
          </group>
          <group group_id="O2">
            <title>Compounded Topical Anesthetic Ointment</title>
            <description>compounded topical anesthetic ointment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Each Category of the Investigator's Evaluation of Subject's Pain Scale Three Hours After Injection of Restylane® Into the Nasolabial Folds</title>
          <description>Number of participants in each category of the Investigator's Evaluation of Subject's Pain scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) three hours after injection of Restylane® into the nasolabial folds</description>
          <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Each Category of the Blinded Evaluator's Evaluation of Subject's Pain Scale Upon First Needle Stick of Injection of Restylane® Into the Nasolabial Folds</title>
        <description>Number of participants in each category of the Blinded Evaluator's Evaluation of Subject's Pain scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) upon first needle stick of an injection of Restylane® into the nasolabial folds</description>
        <time_frame>upon first needle stick of injection of Restylane® into the nasolabial folds</time_frame>
        <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Pliaglis® Cream</title>
            <description>Pliaglis® Cream</description>
          </group>
          <group group_id="O2">
            <title>Compounded Topical Anesthetic Ointment</title>
            <description>compounded topical anesthetic ointment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Each Category of the Blinded Evaluator's Evaluation of Subject's Pain Scale Upon First Needle Stick of Injection of Restylane® Into the Nasolabial Folds</title>
          <description>Number of participants in each category of the Blinded Evaluator's Evaluation of Subject's Pain scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) upon first needle stick of an injection of Restylane® into the nasolabial folds</description>
          <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Each Category of the Blinded Evaluator's Evaluation of Subject's Pain Scale Immediately After Injection of Restylane® Into the Nasolabial Folds</title>
        <description>Number of participants in each category of the Blinded Evaluator's Evaluation of Subject's Pain scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) immediately after injection of Restylane® into the nasolabial folds</description>
        <time_frame>immediately after injection of Restylane® into the nasolabial folds</time_frame>
        <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Pliaglis® Cream</title>
            <description>Pliaglis® Cream</description>
          </group>
          <group group_id="O2">
            <title>Compounded Topical Anesthetic Ointment</title>
            <description>compounded topical anesthetic ointment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Each Category of the Blinded Evaluator's Evaluation of Subject's Pain Scale Immediately After Injection of Restylane® Into the Nasolabial Folds</title>
          <description>Number of participants in each category of the Blinded Evaluator's Evaluation of Subject's Pain scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) immediately after injection of Restylane® into the nasolabial folds</description>
          <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Each Category of the Blinded Evaluator's Evaluation of Subject's Pain Scale One Hour After Injection of Restylane® Into the Nasolabial Folds</title>
        <description>Number of participants in each category of the Blinded Evaluator's Evaluation of Subject's Pain scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) one hour after an injection of Restylane® into the nasolabial folds</description>
        <time_frame>one hour after injection of Restylane® into the nasolabial folds</time_frame>
        <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Pliaglis® Cream</title>
            <description>Pliaglis® Cream</description>
          </group>
          <group group_id="O2">
            <title>Compounded Topical Anesthetic Ointment</title>
            <description>compounded topical anesthetic ointment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Each Category of the Blinded Evaluator's Evaluation of Subject's Pain Scale One Hour After Injection of Restylane® Into the Nasolabial Folds</title>
          <description>Number of participants in each category of the Blinded Evaluator's Evaluation of Subject's Pain scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) one hour after an injection of Restylane® into the nasolabial folds</description>
          <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Each Category of the Blinded Evaluator's Evaluation of Subject's Pain Scale Three Hours After Injection of Restylane® Into the Nasolabial Folds</title>
        <description>Number of participants in each category of the Blinded Evaluator's Evaluation of Subject's Pain scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) three hours after injection of Restylane® into the nasolabial folds</description>
        <time_frame>three hours after injection of Restylane® into the nasolabial folds</time_frame>
        <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Pliaglis® Cream</title>
            <description>Pliaglis® Cream</description>
          </group>
          <group group_id="O2">
            <title>Compounded Topical Anesthetic Ointment</title>
            <description>compounded topical anesthetic ointment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Each Category of the Blinded Evaluator's Evaluation of Subject's Pain Scale Three Hours After Injection of Restylane® Into the Nasolabial Folds</title>
          <description>Number of participants in each category of the Blinded Evaluator's Evaluation of Subject's Pain scale (0 = No pain; 1 = Slight pain; 2 = Moderate pain; 3 = Severe pain) three hours after injection of Restylane® into the nasolabial folds</description>
          <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Yes/no Answers to Question to Investigator &quot;Did the Topical Anesthetics Provide Adequate Anesthesia for the Injections of Restylane® Into the Nasolabial Folds Procedure?&quot; Day of Injection of Restylane® Into Nasolabial Folds</title>
        <description>Number of participants with yes or no answers to question asked to investigator on the day of injection of Restylane® into the nasolabial folds &quot;Did the topical anesthetics provided adequate anesthesia for the injections of Restylane® into the nasolabial folds procedure?&quot;</description>
        <time_frame>Day of injection of Restylane® into the nasolabial folds</time_frame>
        <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Pliaglis® Cream</title>
            <description>Pliaglis® Cream</description>
          </group>
          <group group_id="O2">
            <title>Compounded Topical Anesthetic Ointment</title>
            <description>compounded topical anesthetic ointment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Yes/no Answers to Question to Investigator &quot;Did the Topical Anesthetics Provide Adequate Anesthesia for the Injections of Restylane® Into the Nasolabial Folds Procedure?&quot; Day of Injection of Restylane® Into Nasolabial Folds</title>
          <description>Number of participants with yes or no answers to question asked to investigator on the day of injection of Restylane® into the nasolabial folds &quot;Did the topical anesthetics provided adequate anesthesia for the injections of Restylane® into the nasolabial folds procedure?&quot;</description>
          <population>ITT (Intent to Treat), LOCF (Last Observation Carried Forward)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Tolerability Assessments Resulting in Adverse Events From Baseline to Two Days After Injection of Restylane® Into the Nasolabial Folds</title>
        <description>Number of participants w/ tolerability assessments (erythema, edema, blanching) resulting in adverse events from Baseline to two days after injection of Restylane® into the nasolabial folds</description>
        <time_frame>Baseline to two days after injection of Restylane® into the nasolabial folds</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>Pliaglis® Cream</title>
            <description>Pliaglis® Cream</description>
          </group>
          <group group_id="O2">
            <title>Compounded Topical Anesthetic Ointment</title>
            <description>compounded topical anesthetic ointment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tolerability Assessments Resulting in Adverse Events From Baseline to Two Days After Injection of Restylane® Into the Nasolabial Folds</title>
          <description>Number of participants w/ tolerability assessments (erythema, edema, blanching) resulting in adverse events from Baseline to two days after injection of Restylane® into the nasolabial folds</description>
          <population>Safety</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to two days after Restylane® injections</time_frame>
      <desc>Subjects were asked if there had been any change in their health at each study visit; information obtained was recorded as adverse event9s), if applicable.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pliaglis® Cream and Compounded Topical Anesthetic Ointment</title>
          <description>Apply Pliaglis® Cream on one side of the face and compounded topical anesthetic ointment on the other side of the face; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and compounded topical anesthetic ointment was used on the other side of the face prior to injection of Restylane® into the nasolabial folds.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Implant site bruising</sub_title>
                <description>Bruising is at Restylane® injection site</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The principal investigator has the right to publish or present the data resulting from this study, with agreed upon reviews by all interested parties, and in accordance with any confidentiality agreements that may exist.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ron W. Gottschalk, MD / Medical Director</name_or_title>
      <organization>Galderma Laboratories, L.P.</organization>
      <phone>817-961-5358</phone>
      <email>ron.gottschalk@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

